---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-210079"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:51:56.489690+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Apellis exchanges $22.5M convertible notes for shares; prior $75.6M exchange closed Aug 1

## Summary
- Signed exchange agreements on July 28 to convert $22.5M in 3.5% convertible notes due 2026 into common stock.
- Consideration includes 456,128 shares fixed plus additional shares based on volume-weighted average price over 3 trading days.
- Prior exchange of $75.6M principal closed Aug 1, issuing 2,334,014 shares—combined ~$98.1M of notes converted.
- Shares issued in private placement to QIBs and accredited investors; no registration under Securities Act.
- No cash interest paid on exchanged notes; holders waived accrued interest and conversion rights.

## SEC filing metadata
- accession: 0001193125-22-210079
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312522210079/0001193125-22-210079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312522210079/d385179d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-210079
- JSON: https://secwatch.observer/filing/0001193125-22-210079.json
- Plain text: https://secwatch.observer/filing/0001193125-22-210079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.